| |
|
|
|
Adamas Pharmaceuticals Inc.  
|
|
3.98 -0.02 (-0%) |
10-18 16:00 |
|
Open: |
3.97 |
Pre close: |
4 |
Target:
|
7.11
|
|
High: |
4.01 |
Low: |
3.86 |
Resistance:
|
6.09
7.78
|
|
Volume: |
313,160 |
Market Cap: |
111M |
Support:
|
3.35
2.79
|
|
|
|
|
|
Technical Analysis |
|
Moving Averages |
MA(5):
|
3.99
 |
MACD |
MACD(12,26):
|
-0.60 |
|
MA(20): |
4.84  |
Signal(12,26,9): |
-0.58 |
|
MA(100): |
5.62 |
Stochastic Oscillator |
%K(14,3):
|
18.44 |
|
MA(250): |
7.62 |
%D(3): |
16.57 |
|
Average Volume(K) |
3-Month: |
58832
|
52-Week |
High:
|
18.51 |
|
10-Days: |
66985 |
Low: |
3.35 |
|
RSI |
RSI(14):
|
35.20 |
Change(%): |
-77.7 |
|
Financials, Statistics and Valuation |
|
EPS |
-4.252 |
Return on Equity (ttm) |
-125.8 |
Shares Out. (M) |
27.77 |
|
EPS Est. Current Year |
-3.770 |
Return on Assets (ttm) |
-26.9 |
Shares Float (M) |
18.41 |
|
EPS Est. Next Year |
-3.420 |
PEG Ratio |
-0.02 |
% Held by Insiders |
2.11 |
|
EPS Est. Next Quarter |
-1.170 |
Qtrly Rev. Growth |
67.8 |
% Held by Institutions |
114.84 |
|
Forward EPS |
-3.948 |
Gross Profit (p.s.) |
1.203 |
Shares Short (K) |
2850 |
|
Book Value (p.s.) |
1.540 |
EBITDA (p.s.) |
-3.638 |
P/E |
-0.94 |
|
Sales Per Share |
0.000 |
Qtrly Earnings Growth |
0.00 |
P/BV |
2.58 |
|
Profit Margin |
-241.41 |
Operating Cash Flow
(M) |
-90.65 |
P/S |
62798068.00 |
|
Operating Margin |
-212.17 |
Levered Free Cash Flow
(M) |
-64.55 |
P/CF |
-1.22 |
|
|
|
|
|
|
